68市場におけるパーキンソン病 - 疾患概要、製品プロファイル、患者フロー、競合評価、2033年までの売上予測

2023年のパーキンソン病（PD）治療薬の売上高は主要7ヶ国市場全体で約34億米ドルとなりました。2023年の推定薬剤売上高は21億米ドルで、米国がPD市場を独占し、主要7ヶ国市場の売上高の63.3%を占めています。この高い市場シェアは、主にPDの有病人口が多いことと、米国では主要7ヶ国市場の他の国に比べて薬剤費が著しく高いことによるものです。EU5ヶ国市場の2023年の売上高は6億7,430万米ドルで、世界市場の20.0%を占めました。日本の2023年の売上高は5億6,040万米ドルで、世界市場全体の16.6%を占めています。

世界のPD市場は2033年までにCAGR8.9%で拡大し、約79億米ドル規模に成長すると予測されています。米国は2033年も市場リーダーの座を維持すると予想されます。

68市場全体では、パーキンソン病市場の売上は2023年に57億米ドルで、2033年には124億米ドルに成長します。主要7ヶ国市場（米国、フランス、ドイツ、イタリア、スペイン、英国、日本）は、2023年と2033年の68市場の売上高のそれぞれ約59.5%と63.5%を占めています。

当レポートは、世界68の市場における68市場におけるパーキンソン病について詳細に調査し、疾患概要、製品プロファイル、国別動向、2033年までの売上予測などを提供しています。

目次

第1章 エグゼクティブサマリー

• 概要
• 68市場の要約統計
• 主要7ヶ国市場における事象：68市場の予測

第2章 付録

• 略語
• 調査手法
• 1次調査-このレポートのためにインタビューを受けた主要なオピニオンリーダー
• 1次調査-処方者調査
• 著者について

GlobalDataについて

お問い合わせ

This report covers the 68 geographical markets and provides an Excel-based forecast model for the Parkinson's Disease market through 2033.

GlobalData estimates that drug sales for PD in 2023 were approximately $3.4 billion across the 7MM. With an estimated $2.1 billion in drug sales in 2023, the US dominated the PD market, contributing 63.3% of the sales in the 7MM. The high market share is primarily due to the large PD prevalent population coupled with the cost of drugs, which is significantly higher in the US compared to other countries in the 7MM. The 5EU market contributed $674.3 million in sales in 2023, accounting for 20.0% of the global market. Japan contributed sales of $560.4 million in 2023, representing 16.6% of the total global market. GlobalData anticipates that the PD market will grow to be worth approximately $7.9 billion by 2033, at a compound annual growth rate (CAGR) of 8.9%. The US is expected to maintain its position as the market leader in 2033.

Across the 68 markets, sales in the Parkinson's Disease market were $5.7billion in 2023, growing to $12.4 billion in 2033. The seven major markets (US, France, Germany, Italy, Spain, UK, and Japan) represent approximately 59.5% and 63.5% of 68-market sales in 2023 and 2033, respectively.

Scope

• Overview of Parkinson's Disease, including epidemiology, symptoms, diagnosis, and disease management.
• Annualized Parkinson's Disease therapeutics market revenue, cost of therapy per patient, and treatment usage patterns forecast from 2023 to 2033.
• Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping, and implications of these factors for the Parkinson's therapeutics market.
• Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for Parkinson's treatment. The most promising candidates in late-stage development are profiled.
• Analysis of the current and future market competition in the global Parkinson's Disease therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to Buy

• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving the 7MM Parkinson's Disease therapeutics market.
• Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the 7MM Parkinson's Disease therapeutics market in the future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
• Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Table of Contents

1 Executive Summary

• 1.1 Overview
• 1.2 68M summary statistics
• 1.3 Key 7MM events driving the 68M forecast extrapolation

2 Appendix

• 2.1 Abbreviations
• 2.2 Methodology
  • 2.2.1 Patient-based forecast methodology
  • 2.2.2 68M forecast extrapolation methodology
• 2.3 Primary research - key opinion leaders interviewed for this report
  • 2.3.1 Key opinion leaders
• 2.4 Primary research - prescriber survey
• 2.5 About the authors
  • 2.5.1 Analyst
  • 2.5.2 Managing analyst
  • 2.5.3 Therapy area directors
  • 2.5.4 Epidemiologist
  • 2.5.5 Epidemiology reviewers
  • 2.5.6 Vice President of Disease Intelligence and Epidemiology
  • 2.5.7 Global Head of Pharma, Research, Analysis and Competitive Intelligence

About GlobalData

Contact Us